Global Shigella Vaccines Market Overview:
Shigellosis is an infectious disease caused by a group of bacteria called Shigella. Shigella is a gram-negative pathogenic enterobacterium that causes severe diarrhea and dysentery in humans. Symptoms associated with Shigella infection include fever, stomach pain, tenesmus, watery diarrhea, vomiting, dehydration, and convulsions.
- Increase in Incidence of Shigella Infection across the Globe
- Lack of Vaccination for Shigella Infection
- Ongoing Clinical Trials and Studies on Development of Treatment for Combating Shigella Species
- High Cost Associated With Storage And Supply Of Vaccines
- Rise in Research & Development
- Increasing Immunization Programs And Government Initiatives
- Lack of Awareness of the Harmful Effects of Shigella
The global Shigella Vaccines market is fragmented and the leading pharmaceutical companies are working on their research and development team to clear all the clinical trials and get approval from the FDA to launch its vaccines.
Some of the key players profiled in the report are MSD Wellcome Trust Hilleman Laboratories Pvt. Ltd. (United States), Novartis (Switzerland) and GlaxoSmithKline plc (United Kingdom). Considering Market by Species, the sub-segment i.e. Shigella Sonnei will boost the Shigella Vaccines market.
Latest Market Insights:
In Oct 2019, The European Vaccine Initiative (EVI) and Hilleman Laboratories, announced partnership for the development of new shigella vaccine.
In Sept 2019, LimmaTech Biologics AG and GlaxoSmithKline plc., collaboratively initiated Phase I/II clinical trial of 4-valent candidate vaccine in Kenya to prevent diarrheal disease cause due to Shigella in the developing economies.
Data related to EXIM [Export- Import], production & consumption by country or regional level break-up can be provided based on client request**
** Confirmation on availability of data would be provided prior to purchase
The top-down and bottom-up approaches are used to estimate and validate the size of the Global Shigella Vaccines market.
In order to reach an exhaustive list of functional and relevant players various industry classification standards are closely followed such as NAICS, ICB, SIC to penetrate deep in important geographies by players and a thorough validation test is conducted to reach most relevant players for survey in Shigella Vaccines market.
In order to make priority list sorting is done based on revenue generated based on latest reporting with the help of paid databases such as Factiva, Bloomberg etc.
Finally the questionnaire is set and specifically designed to address all the necessities for primary data collection after getting prior appointment by targeting key target audience that includes Shigella Vaccines Manufacturers, Shigella Vaccines Suppliers, Raw Material Suppliers, Research and Development Organization, Potential Investors and Government Agencies.
This helps us to gather the data related to players revenue, operating cycle and expense, profit along with product or service growth etc.
Almost 70-80% of data is collected through primary medium and further validation is done through various secondary sources that includes Regulators, World Bank, Association, Company Website, SEC filings, OTC BB, USPTO, EPO, Annual reports, press releases etc.